THE ARISING · Longevity & Healthspan
Experimental retatrutide reduced sleep apnea events in two trials
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
Two late-stage randomized trials found that retatrutide, an investigational weekly injection, reduced breathing interruptions during sleep more than placebo. The Lilly-funded trials enrolled 691 adults with moderate-to-severe obstructive sleep apnea and a body-mass index of at least 27. One trial enrolled adults without type 2 diabetes; the other enrolled adults with it.
After 80 weeks, the two higher-dose study groups without diabetes had about 22 to 24 fewer breathing events per hour than placebo. In the trial with diabetes, the difference was about 14 to 15 per hour. These numbers compare changes between randomized groups; they are not the number of events participants still had at the end. A separate analysis by original treatment assignment produced similar estimates.
Participants on retatrutide also lost more weight. The most common side effects involved the digestive system. The trials compared the drug with placebo, not with a positive airway pressure device, and they did not establish that patients could stop their existing treatment. Retatrutide remains investigational and is not FDA-approved.
Primary source: TRIUMPH-1-OSA and TRIUMPH-2-OSA in NEJM · Investigational status